TY - JOUR
T1 - Retrospective analysis of children with high-risk acute myeloid leukemia who underwent allogeneic hematopoietic stem cell transplantation following complete remission with initial induction chemotherapy in the AML-05 clinical trial
AU - Hyakuna, Nobuyuki
AU - Hashii, Yoshiko
AU - Ishida, Hiroyuki
AU - Umeda, Katsutsugu
AU - Takahashi, Yoshiyuki
AU - Nagasawa, Masayuki
AU - Yabe, Hiromasa
AU - Nakazawa, Yozo
AU - Koh, Katsuyoshi
AU - Goto, Hiroaki
AU - Fujisaki, Hiroyuki
AU - Matsumoto, Kimikazu
AU - Kakuda, Harumi
AU - Yano, Michihiro
AU - Tawa, Akio
AU - Tomizawa, Daisuke
AU - Taga, Takashi
AU - Adachi, Souichi
AU - Kato, Koji
N1 - Funding Information:
We thank all doctors who participated in the JPLSG AML-05 study. Most of the transplant-related data on TRUMP were kindly provided by the Japan Society for Hematopoietic Cell Transplantation. We would like to thank Editage (www.editage.jp) for English language editing. N.H., Y.H., and K.K. participated actively in the study conception and design; N.H. performed the data analysis and interpretation and was the main author of the study. H.I., K.U., Y.T., M.N., H.Y., Y.N., K.K., H.G., H.F., K.M., H.K., M.Y., A.T., D.T., T.T., and S.A. carried out the study, reviewed the results, and approved the final manuscript. Research data are not shared.
PY - 2019
Y1 - 2019
N2 - In the AML-05 clinical trial conducted by the Japanese Pediatric Leukemia/Lymphoma Group from 2006 to 2010, children with high-risk acute myeloid leukemia (HR AML) received allogeneic hematopoietic stem cell transplantation (allo-HSCT) at first complete remission (CR1). The aim of this study was to investigate the impact of allo-HSCT on the outcome of HR AML. Patients with either monosomy 7, 5q−, t(16;21), Ph1, FLT3-ITD, or induction failure after the first course of chemotherapy were eligible for transplant. Of 53 children with HR AML, 51 received allo-HSCT—45 in CR1, five in CR2, and one with non-CR. t(8;21), t(9;11), and t(16;21) abnormalities were identified in eight, five, and four patients, respectively. The stem cell sources varied—bone marrow in 30 patients, peripheral blood in three, and cord blood in 18. The median follow-up was 62 months. The overall survival (OS) rates at 3 years were 73% and 25% for patients who received transplant at CR1 and ≥CR2, respectively. Multivariable analysis showed that patients with chronic graft-versus-host disease (cGVHD) had better OS. This study supports that allo-HSCT is a suitable treatment for HR AML in CR1. The favorable outcome associated with cGVHD indicates that a graft-versus-leukemia effect might be occurring.
AB - In the AML-05 clinical trial conducted by the Japanese Pediatric Leukemia/Lymphoma Group from 2006 to 2010, children with high-risk acute myeloid leukemia (HR AML) received allogeneic hematopoietic stem cell transplantation (allo-HSCT) at first complete remission (CR1). The aim of this study was to investigate the impact of allo-HSCT on the outcome of HR AML. Patients with either monosomy 7, 5q−, t(16;21), Ph1, FLT3-ITD, or induction failure after the first course of chemotherapy were eligible for transplant. Of 53 children with HR AML, 51 received allo-HSCT—45 in CR1, five in CR2, and one with non-CR. t(8;21), t(9;11), and t(16;21) abnormalities were identified in eight, five, and four patients, respectively. The stem cell sources varied—bone marrow in 30 patients, peripheral blood in three, and cord blood in 18. The median follow-up was 62 months. The overall survival (OS) rates at 3 years were 73% and 25% for patients who received transplant at CR1 and ≥CR2, respectively. Multivariable analysis showed that patients with chronic graft-versus-host disease (cGVHD) had better OS. This study supports that allo-HSCT is a suitable treatment for HR AML in CR1. The favorable outcome associated with cGVHD indicates that a graft-versus-leukemia effect might be occurring.
UR - http://www.scopus.com/inward/record.url?scp=85069679496&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069679496&partnerID=8YFLogxK
U2 - 10.1002/pbc.27875
DO - 10.1002/pbc.27875
M3 - Article
C2 - 31309713
AN - SCOPUS:85069679496
VL - 66
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
SN - 1545-5009
IS - 10
M1 - e27875
ER -